Privia Health Group/$PRVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Privia Health Group
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
- Ticker
- $PRVA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,226
- Headquarters
- Arlington, United States
- Website
- www.priviahealth.com
PRVA Metrics
BasicAdvanced
$3.1B
94.08
$0.26
0.75
-
Price and volume
Market cap
$3.1B
Beta
0.75
52-week high
$28.82
52-week low
$18.92
Average daily volume
1.4M
Financial strength
Current ratio
1.631
Quick ratio
1.586
Long term debt to equity
0.007
Total debt to equity
0.009
Profitability
EBITDA (TTM)
63.811
Gross margin (TTM)
9.91%
Net profit margin (TTM)
1.43%
Operating margin (TTM)
2.10%
Effective tax rate (TTM)
37.40%
Revenue per employee (TTM)
$1,990,000
Management effectiveness
Return on assets (TTM)
2.19%
Return on equity (TTM)
4.72%
Valuation
Price to earnings (TTM)
94.08
Price to revenue (TTM)
1.256
Price to book
3.82
Price to tangible book (TTM)
8.11
Price to free cash flow (TTM)
28.303
Free cash flow yield (TTM)
3.53%
Free cash flow per share (TTM)
0.863
Growth
Revenue change (TTM)
19.19%
Earnings per share change (TTM)
85.30%
3-year revenue growth (CAGR)
15.47%
3-year earnings per share growth (CAGR)
-5.34%
What the Analysts think about PRVA
Analyst ratings (Buy, Hold, Sell) for Privia Health Group stock.
Analyst projections of the future price of Privia Health Group stock.
Bulls say / Bears say
Implemented providers grew 12.2% and value-based-care attributed lives rose 19.2% year on year in the third quarter. Privia raised its 2026 adjusted EBITDA guidance to $154–157 million, above the top of its original range. (Privia Health Group)
Profit is growing faster than care margin: year-to-date adjusted EBITDA rose 21.9%, against 15.4% growth in care margin, while adjusted EBITDA as a share of care margin improved to 28.8% from 27.2%. This points to operating leverage as the platform scales. (Privia Health Group)
The $36 million acquisition of American Choice Healthcare adds an ACO with more than 36,000 attributed lives and extends Privia into three new states. The company expects the deal to add to attributed lives and adjusted EBITDA in 2027. (Privia Health Group)
Growth slowed in the latest quarter: adjusted EBITDA rose 6.3% and platform contribution 4.8%, versus year-to-date growth of 21.9% and 16.8%, respectively. If that weaker quarterly pace persists, it could challenge expectations for continued operating leverage. (Privia Health Group)
Cash conversion is exposed to timing: management expects about 70% of adjusted EBITDA to convert to free cash flow in 2026, assuming the Medicare shared-savings settlement and related provider payments occur before year-end. A delay could push cash receipts into a later period. (Privia Health Group)
Management warned that regulatory and reimbursement changes, and shifts in attributed lives between programmes, could disrupt performance across states. That leaves Privia exposed to changes in contract economics and patient mix. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
PRVA Financial Performance
Revenues and expenses
PRVA Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRVA News
AllArticlesVideos
Funds containing PRVA
AllUSDEURGBP
Fund name | Fund size | $PRVA weighting |
|---|---|---|
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.18% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.18% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.10% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.